Fundz
Real-time · AI · Cross-signal

CorFlow Therapeutics AG just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on CorFlow Therapeutics AG, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

CorFlow Therapeutics AG raised €44 million in a Series B funding round co-led by Broadview Ventures and Panakes Partners to support the advancement of a novel diagnostic and drug delivery platform for microvascular obstruction in heart attack patients.

PRIVATESep 10, 2024•over 1 year ago

Amount Raised

€44 Million

Round Type

series b

BaarBiotechnologyHealth CareMedicalMedical DeviceTherapeutics

Investors

Monte Carlo CapitalKofa HealthcareUnorthodox VenturesM&L InvestmentsWellington PartnersLaerdal Million Lives FundMerieux Equity Partners415 CapitalPanakes PartnersBroadview Ventures

Description

CorFlow Therapeutics AG announced today that it has raised €44 million in Series B funding. This financing will support the MOCA II pivotal study intended to gain US market clearance for their CoFl system in diagnosing microvascular obstruction in heart attack patients.

Company Information

Company

CorFlow Therapeutics AG

Location

Baar, Zug, Switzerland

About

CorFlow Therapeutics AG is focused on developing innovative solutions for the diagnosis and treatment of microvascular obstruction in heart attack patients. Their CoFl system aims to provide timely and accurate detection of microvascular obstruction during catheter laboratory procedures. The company is committed to improving patient outcomes and reducing healthcare costs associated with cardiovascular diseases. CorFlow's technology seamlessly integrates with existing medical workflows to enhance treatment delivery.

Predictive Intelligence
Strategic

ML-powered predictions for CorFlow Therapeutics AG's next move

Learn about Strategic plan

Related People

Suggested for you
2 contacts

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies.

Watching CorFlow Therapeutics AG? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan